New England Journal of Medicine published the Phase 1 trial data on April 10, 2021 in original article entitled “Oncolytic HSV-1 Immunovirotherapy for Pediatric High-Grade Gliomas”
G207 alone or in combination with radiation is well tolerated by pediatric patients
G207 showed evidence of radiographic, neuropathological, or clinical response in 11 of 12 patients
G207 converted immunologically “cold” tumors to “hot”
Phase 2 program to launch in 2021 aimed at market approval for G207
Additionally, a presentation of the findings of the Phase I trial was made by Gregory K. Friedman, MD, University of Alabama Birmingham and the Phase 1 G207 clinical trial Principal Investigator, at the annual AACR (American Association for Cancer Research) virtual meeting on April 10, 2021.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok